Biohaven Buy: Upgrade Back to Buy as Protein Degrader Programs Move to Pivotal Studies
We upgrade Biohaven (BHVN) to Buy after management pushed forward multiple protein degrader programs into pivotal study initiation. With a market cap near $2.02B, cash per share of $5.24 (implying roughly $789M of cash on the balance sheet), and a technical breakout from key moving averages, the risk-reward favors a disciplined long position. This …